$IMMP

Immutep Limited (ASX: IMM; NASDAQ: IMMP) outlined its development strategy for eftilagimod alfa (EFTI), focusing on head and neck squamous cell carcinoma (HNSCC) and soft tissue sarcoma (STS). The company identified manufacturing differences between EFTI batches and plans a new 200 L scale production run. Clinical trials are targeted for 2H 2027, subject to regulatory and partnering decisions. EFTI has received Fast Track and Orphan Drug designations from the FDA.

Immutep Limited (ASX: IMM, NASDAQ: IMMP) said the USPTO granted US patent 12,673,088 covering methods to treat cancer using eftilagimod alfa with anti-PD-1 or anti-PD-L1 antibodies. The patent expires 20 Jan 2036 and is the fourth US patent in the series, following earlier grants from 2020, 2021 and 2023.

Immutep Limited (IMMP) reported mature overall survival from its INSIGHT-003 Phase I trial in first-line non-squamous NSCLC. Median OS was 30.9 months (51 patients, 30+ months follow-up), including low/no PD-L1. No new safety signals. The company also updated that Phase III TACTI-004 was discontinued after futility.

SueWallSt says Immutep (NASDAQ: IMMP) disclosed on March 13, 2026 that its TACTI-004 Phase III trial was discontinued for futility, after an IDMC recommendation. The article states IMMP shares fell about 83% (from $2.76 to $0.48). It alleges investors were misled from March 24, 2025 to March 12, 2026 and notes a July 6, 2026 lead-plaintiff deadline.

Prima BioMed (NASDAQ:IMMP) shares fell below their 50-day moving average of $0.44, trading as low as $0.4205 and last at $0.4446 on Thursday on volume of 2,034,964 shares. The article cites a securities class action over alleged violations and analyst downgrades, including Robert W. Baird cutting its target from $7.00 to $1.00.

Robbins LLP said it is investigating allegations that Immutep Limited (IMMP) misled investors about its TACTI-004 Phase III trial for eftilagimod alfa (efti). A class action was filed for investors who bought IMMP ADRs from March 24, 2025 to March 12, 2026. The complaint cites SEC filings and a Jan. 30, 2026 update, and an IDMC decision to stop the trial on March 13, 2026, after which the ADR fell from $2.76 to $0.48.

Pomerantz LLP said it has informed investors about a class action against Immutep Limited, according to the press release. The notice does not provide case details or financial figures. The filing is relevant for investors because it signals potential legal exposure for the company.

The Schall Law Firm is reminding investors of a class action lawsuit against Immutep Limited (NASDAQ: IMMP) for alleged securities fraud. The lawsuit claims that Immutep made misleading statements regarding its TACTI-004 trial, concealing that it would fail to meet its primary efficacy endpoints. Investors who purchased securities between March 24, 2025, and March 12, 2026, are encouraged to contact the firm before July 6, 2026.

IMMUTEP Ltd director Pete A. Meyers has filed an initial ownership report revealing a direct holding of 4,052,173 Ordinary Shares and several blocks of performance rights over additional shares. These performance rights, totaling over 2.4 million underlying Ordinary Shares, have an exercise price of $0.0000 per share and are subject to specific vesting and expiration dates ranging from October 2026 to December 2030, contingent on Mr. Meyers meeting certain conditions. The filing provides detailed footnotes on the grants, vesting schedules, and expiration terms for each block of performance rights.

Dr. Reddy’s Laboratories announced that its partner, Immutep, has halted the TACTI-004 Phase III trial of Eftilagimod alfa for non-small cell lung cancer due to an independent data monitoring committee's recommendation after a futility analysis. This decision leads to the discontinuation of the trial, an enrollment halt, and a wind-down process. Dr. Reddy’s subsidiary, which holds commercial rights in several territories, has only made the upfront payment and is discussing next steps with Immutep, whose broader pipeline for Eftilagimod alfa remains in focus.